Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD

Open access

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by changes in cell composition that occur throughout disease pathogenesis, which includes the development of fibrosis in a subset of patients. DNA methylation (DNAm) is a plausible mechanism underlying these shifts, considering that DNAm profiles differ across tissues and cell types, and DNAm may play a role in cell-type differentiation. Previous work investigating the relationship between DNAm and fibrosis in NAFLD has been limited by sample size and the number of CpG sites interrogated. Results: Here, we performed an epigenome-wide analysis using Infinium MethylationEPIC array data from 325 individuals with NAFLD, including 119 with severe fibrosis and 206 with no histological evidence of fibrosis. After adjustment for latent confounders, we identified 7 CpG sites whose DNAm associated with fibrosis (p < 5.96 × 10–8). Analysis of RNA-seq data collected from a subset of individuals (N = 56) revealed that gene expression at 288 genes associated with DNAm at one or more of the 7 fibrosis-related CpGs. DNAm-based estimates of cell-type proportions showed that estimated proportions of natural killer cells increased, while epithelial cell proportions decreased with disease stage. Finally, we used an elastic net regression model to assess DNAm as a biomarker of fibrotic stage and found that our model predicted fibrosis with a sensitivity of 0.93 and provided information beyond a model based solely on cell-type proportions. Conclusion: These findings are consistent with DNAm as a mechanism underpinning or marking fibrosis-related shifts in cell composition and demonstrate the potential of DNAm as a possible biomarker of NAFLD fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13148-021-01129-y

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Manhattan plot depicting association between DNAm and fibrosis. The solid horizontal lines indicate the Bonferroni threshold, and the dotted lines indicate the FDR < 0.05 threshold. Covariates include age, sex, BMI, and two latent variables
Fig. 1 Manhattan plot depicting association between DNAm and fibrosis. The solid horizontal lines indicate the Bonferroni threshold, and the dotted lines indicate the FDR < 0.05 threshold. Covariates include age, sex, BMI, and two latent variablesCC BY · PubMed Central
Fig. 2 Boxplot of DNAm proportions against NAFLD fibrosis stage for the most significant CpG site (cg19686543) in the primary analysis
Fig. 2 Boxplot of DNAm proportions against NAFLD fibrosis stage for the most significant CpG site (cg19686543) in the primary analysisCC BY · PubMed Central
Fig. 3 Correlation matrix of the seven NAFLD-related CpG sites from the main analysis
Fig. 3 Correlation matrix of the seven NAFLD-related CpG sites from the main analysisCC BY · PubMed Central
Fig. 4 First row of panels shows estimated proportions of epithelial, fibroblast, and immune cells by fibrotic stage. Second row of panels shows estimated proportions of subsets of immune cells by fibrotic stage
Fig. 4 First row of panels shows estimated proportions of epithelial, fibroblast, and immune cells by fibrotic stage. Second row of panels shows estimated proportions of subsets of immune cells by fibrotic stageCC BY · PubMed Central
Fig. 5 Comparisons with other analyses. A Effect sizes from our primary analysis compared to previous analyses. NASH-related EWAS in liver tissue. Test statistics from our primary analysis compared to B an EWAS investigating the association between hepatic fat accumulation. C An EWAS of inflammation (C-reactive protein) in blood
Fig. 5 Comparisons with other analyses. A Effect sizes from our primary analysis compared to previous analyses. NASH-related EWAS in liver tissue. Test statistics from our primary analysis compared to B an EWAS investigating the association between hepatic fat accumulation. C An EWAS of inflammation (C-reactive protein) in bloodCC BY · PubMed Central
Fig. 6 Number of genes with a significant association with DNAm across the 7 NAFLD-related CpGs
Fig. 6 Number of genes with a significant association with DNAm across the 7 NAFLD-related CpGsCC BY · PubMed Central
Fig. 7 Prediction scores are highly correlated with NAFLD disease stage in independent test data
Fig. 7 Prediction scores are highly correlated with NAFLD disease stage in independent test dataCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 55

Metadata

Authors
Johnson, N. D., Wu, X., Still, C. D., Chu, X., Petrick, A. T., Gerhard, G. S., Conneely, K. N., & DiStefano, J. K.
Affiliations
  • Emory University (US)
  • Translational Genomics Research Institute (US)
  • Temple University (US)
Corresponding author
DiStefano, Johanna K.
Venue
Clinical Epigenetics
Published
2021-08-05
Volume
13
Issue
1
Pages
152-152
ISSN
  • 1868-7075 (ISSN-L)
  • 1868-7083
OpenAlex
W3190108721
Cited by
43
References
56
Citations by year
2026: 3 · 2025: 8 · 2024: 11 · 2023: 10 · 2022: 8 · 2021: 3
FWCI
2.51
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Epigenetics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (DK107735)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
non-alcoholic fatty liver disease, liver fibrosis, DNA methylation, cell type proportions, natural killer cells, liver epithelial cells, epigenome-wide association study, gene expression, disease progression
MeSH terms
Long Term Adverse Effects, Child, Child, Preschool, Female, Humans, Male, Neoplasm Staging, Intensive Care Units, Pediatric, DNA Methylation, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. https://app.cochat.ai/papers/10.1186/s13148-021-01129-y
The paper
Johnson, N. D., Wu, X., Still, C. D., Chu, X., Petrick, A. T., Gerhard, G. S., Conneely, K. N., & DiStefano, J. K. (2021). Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. Clinical Epigenetics. https://doi.org/10.1186/s13148-021-01129-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.